Recombinant Human Nectin-4 Protein, Fc Tag, 100 µg

Background
Nectin-4(Nectin cell adhesion molecule 4) is a Nectin and nectin-like family of cell adhesion molecules. It is found in high levels in normal embryonic and fetal tissues, but decreases after adulthood and is limited in distribution in healthy tissues. Nectin-4 is overexpressed in a variety of tumor cells and promotes tumor cell growth and proliferation. Solid tumors with high expression of Nectin-4 include bladder cancer, pancreatic cancer, triple negative breast cancer, non-small cell lung cancer, stomach cancer, esophageal cancer, ovarian cancer and many other cancers. Studies have found that Nectin-4 promotes tumor cell proliferation, differentiation, migration and invasion by activating the PI3K/Akt pathway, and is believed to play an important role in the occurrence and metastasis of cancer. It is based on these research backgrounds that drug research targeting this target has emerged.

Source
Recombinant Human Nectin-4, Fc Tag (NE4-H5255) is expressed from human 293 cells (HEK293). It contains AA Gly 32 - Ser 349 (Accession # Q96NY8-1).
Predicted N-terminus: Gly 32

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 60.5 kDa. The protein migrates as 65-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 0.1 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin"
Cho, Saade, Nagarajan et al
J Cutan Pathol (2024)
(2) "Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts"
Bahlinger, Branz, Strissel et al
Histopathology (2024)
(3) "An iodine‑labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma"
Ren, Liu, Li et al
Int J Pharm (2023) 651, 123756
Showing 1-3 of 330 papers.